Cat. No.: HY-13761

Teniposide

(Synonyms: VM26)

13 Cited Publications

Customer Review

Based on 13 publication(s) in Google Scholar

Teniposide is a podophyllotoxin derivative, acts as a topoisomerase II inhibitor, and used as a chemotherapeutic agent.

For research use only. We do not sell to patients.

Purity: 98.40%
CAS No.: 29767-20-2
Formula: C₃₂H₃₂O₁₃S
Molecular Weight:656.65

Storage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Teniposide Chemical Structure

CAS No.: 29767-20-2

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (13)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Teniposide is a podophyllotoxin derivative, acts as a topoisomerase II inhibitor, and used as a chemotherapeutic agent.

IC₅₀ & Target^[2]

Topoisomerase II

All Topoisomerase Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	15.8 nM Compound: Ref 34, Cpd 3	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 32992133]
A549	IC₅₀	8.2 μM Compound: Teniposide	Anticancer activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Anticancer activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 32084316]
CWR22R	IC₅₀	0.082 μM Compound: 3	Antiproliferative activity against human 22Rv1 cells after 96 hrs by propidium iodide-based monolayer assay Antiproliferative activity against human 22Rv1 cells after 96 hrs by propidium iodide-based monolayer assay	[PMID: 26854430]
GLC4 cell line	IC₅₀	0.48 μM Compound: Teniposide	Cytotoxic effect against GLC4 (human small cell lung carcinoma cell line) using the microculture tetrazolium (MTT) assay based on continuous incubation Cytotoxic effect against GLC4 (human small cell lung carcinoma cell line) using the microculture tetrazolium (MTT) assay based on continuous incubation	[PMID: 7783142]
GLC4 cell line	IC₅₀	2.8 μM Compound: Teniposide	Cytotoxic effect against GLC4 (human small cell lung carcinoma cell line) using the microculture tetrazolium (MTT) assay based on 2 hr incubation Cytotoxic effect against GLC4 (human small cell lung carcinoma cell line) using the microculture tetrazolium (MTT) assay based on 2 hr incubation	[PMID: 7783142]
HeLa	ED₅₀	0.3 μg/mL Compound: 5	Cytotoxicity against human HeLa cells after 4 days by trypan blue assay Cytotoxicity against human HeLa cells after 4 days by trypan blue assay	[PMID: 1602298]
HeLa	IC₅₀	14.9 μM Compound: Teniposide	Anticancer activity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Anticancer activity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 32084316]
HepG2	ED₅₀	40.46 mg/kg Compound: Teniposide	Antitumor activity against human HepG2 xenografted in ip dosed BALB/c nude mouse administered for 20 days and measured after 20 days by electronic caliper method Antitumor activity against human HepG2 xenografted in ip dosed BALB/c nude mouse administered for 20 days and measured after 20 days by electronic caliper method	[PMID: 32084316]
HepG2	IC₅₀	4.3 μM Compound: Teniposide	Anticancer activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 32084316]
HepG2	IC₅₀	62.7 μM Compound: Teniposide	Poison activity at topoisomerase-2 in human HepG2 cell lysate assessed as topoisomerase-2 band depletion after 3 hrs by Western blot analysis Poison activity at topoisomerase-2 in human HepG2 cell lysate assessed as topoisomerase-2 band depletion after 3 hrs by Western blot analysis	[PMID: 32084316]
HMEC	IC₅₀	12.4 μM Compound: Teniposide	Cytotoxicity against human HMEC cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human HMEC cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 32084316]
L02	IC₅₀	11.5 μM Compound: Teniposide	Cytotoxicity against human HL7702 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human HL7702 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 32084316]
MCF7	IC₅₀	0.125 μM Compound: 3	Antiproliferative activity against human MCF7 cells after 96 hrs by propidium iodide-based monolayer assay Antiproliferative activity against human MCF7 cells after 96 hrs by propidium iodide-based monolayer assay	[PMID: 26854430]
MCF7	IC₅₀	11.1 μM Compound: Teniposide	Anticancer activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 32084316]
MCF7	IC₅₀	15.8 nM Compound: Ref 34, Cpd 3	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 32992133]
MRC5	IC₅₀	12.2 μM Compound: Teniposide	Cytotoxicity against human MRC5 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 32084316]
PC-3	IC₅₀	15.8 nM Compound: Ref 34, Cpd 3	Antiproliferative activity against human PC3 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human PC3 cells incubated for 72 hrs by MTT assay	[PMID: 32992133]
RPMI 8402	IC₅₀	0.22 μM Compound: VM-26	Cytotoxic activity against human lymphoblast tumor cell line RPMI8402 after 4 days of treatment Cytotoxic activity against human lymphoblast tumor cell line RPMI8402 after 4 days of treatment	[PMID: 12747798]
RPMI 8402	IC₅₀	0.22 μM Compound: VM-26	Cytotoxicity against human lymphoblast tumor cell line RPM18402 Cytotoxicity against human lymphoblast tumor cell line RPM18402	[PMID: 12392745]
RPMI 8402	IC₅₀	0.28 μM Compound: VM-26	Cytotoxicity using camptothecin-resistant variant of RPM18402 (CPT-K5) possessing functional, but mutant TOP-1 Cytotoxicity using camptothecin-resistant variant of RPM18402 (CPT-K5) possessing functional, but mutant TOP-1	[PMID: 12392745]

In Vitro

Teniposide is a topoisomerase II inhibitor. Teniposide (VM-26, 0.15-45 mg/L) inhibits the proliferation of Tca8113 cells in a dose-dependent manner, with an IC₅₀ of 0.35 mg/L. Teniposide (5 mg/L) induces apoptosis of Tca8113 cells. Teniposide (5.0 mg/L) causes cell arrested at G2/M phase in Tca8113 cells^[2]. Teniposide is active on primary cultured glioma cells from patients, when the level of miR-181b is high in the cells, with an IC₅₀ of 1.3 ± 0.34 μg/mL. Cells treated with teniposide with low MDM2 have decreased viability compared with control cells, and the IC₅₀ decreases from 5.86 ± 0.36 μg/mL to 2.90 ± 0.35 μg/mL upon MDM2 suppression. Teniposide also inhibits the viability of glioma cell with high level of miR-181b, through mediation of MDM2^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Teniposide (0.5 mg/kg, i.p.) significantly increases micronucleated polychromatic erythrocyte (MNPCE) frequencies, which is directly related to bone marrow toxicity as significant suppression of bone marrow is noted. Teniposide (24 mg/kg, i.p.) markedly decreases the frequencies of BrdU-labelled sperm. Teniposide (12, 24 mg/kg, i.p.) also dramatically induces disomic sperm in the germ cell of male mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 29767-20-2
Appearance Solid
Molecular Weight 656.65
Formula C₃₂H₃₂O₁₃S
Color White to off-white
SMILES

O=C1OC[C@]2([H])[C@H](O[C@H]3[C@@H]([C@H]([C@@H]([C@@H](CO4)O3)O[C@@H]4C5=CC=CS5)O)O)C6=C(C=C7OCOC7=C6)[C@@H](C8=CC(OC)=C(O)C(OC)=C8)[C@]21[H]
Synonyms

VM26
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (13)

All ELISART-PCRWBHistological Imaging/Staining

Sort by:

Journal Impact Factor

Cell Mol Immunol

Chaperone- and PTM-mediated activation of IRF1 tames radiation-induced cell death and the inflammatory response. [Abstract]

2024 Aug;21(8):856-872. PMID: 38849539
Cell Death Dis

DEPTOR is a direct p53 target that suppresses cell growth and chemosensitivity. [Abstract]

2020 Nov 12;11(11):976. PMID: 33184290
J Immunother Cancer

Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC. [Abstract]

2022 Aug;10(8):e004006. PMID: 36002188

Teniposide purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2022 Aug;10(8):e004006. [Abstract]

Teniposide (10.7 μM for Hep3B cells; 26.15 μM for Huh7 cells; 24 h) significantly increased the IFN-β secretion in Hep3B and Huh7 cells.

Teniposide purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2022 Aug;10(8):e004006. [Abstract]

Teniposide (10.7 μM for Hep3B cells; 26.15 μM for Huh7 cells; 24 h) significantly increased the mRNA expression of IFIT1, IFIT2, CCL5 and CXCL10 in Hep3B and Huh7 cells.

Teniposide purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2022 Aug;10(8):e004006. [Abstract]

Teniposide (10.7 μM for Hep3B cells; 26.15 μM for Huh7 cells; 24 h) increased the cellular protein expression of p-IRF3 and p-P65 in Hep3B and Huh7 cells under normoxic conditions.

Teniposide purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2022 Aug;10(8):e004006. [Abstract]

Teniposide (Teni) (10 mg/kg; i.p.; every other day for twice) increased tumor p-IRF3 expression in mouse HCC tumor model.

Teniposide purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2022 Aug;10(8):e004006. [Abstract]

Teniposide (Teni) (10 mg/kg; i.p.; every other day for twice)significantly increased Ifn-b, Ccl5 and Cxcl10 mRNA expression in the tumor tissues ofmouse HCC tumor model.
Acta Pharmacol Sin

Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. [Abstract]

2021 Jan;42(1):108-114. PMID: 32398685
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
Int Immunopharmacol

Topoisomerase 2 inhibitor etoposide promotes interleukin-10 production in LPS-induced macrophages via upregulating transcription factor Maf and activating PI3K/Akt pathway. [Abstract]

2021 Dec;101(Pt A):108264. PMID: 34715493
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
Mol Pharm

Machine Learning Models Identify New Inhibitors for Human OATP1B1. [Abstract]

2022 Nov 7;19(11):4320-4332. PMID: 36269563
J Cell Mol Med

Inactivation of CDK12 Enhances Mitochondrial Efficiency to Suppress DNA Damage. [Abstract]

2026 Apr;30(7):e71101. PMID: 41896195
BMC Cancer

PROTAC EZH2 degrader-1 overcomes the resistance of podophyllotoxin derivatives in refractory small cell lung cancer with leptomeningeal metastasis. [Abstract]

2024 Apr 22;24(1):504. PMID: 38644473
Mol Biol Cell

Mitotic DNA damage promotes chromokinesin-mediated missegregation of polar chromosomes in cancer cells. [Abstract]

2023 May 1;34(5):ar47. PMID: 36989031
Biomed Pharmacother

Identification of nsp16 inhibitors of SARS -CoV-2, SARS -CoV-1 and MERS-CoV from FDA-approved drugs using in silico and in vitro methods. [Abstract]

2025 Aug:189:118246. PMID: 40543162
Biomed Pharmacother

Characterization of a deazaflavin analog as a potent inhibitor of multidrug resistance-associated protein 1. [Abstract]

2024 Sep:178:117167. PMID: 39032285

Solvent & Solubility

In Vitro:

DMSO : ≥ 30 mg/mL (45.69 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.5229 mL

7.6144 mL

15.2288 mL

5 mM

0.3046 mL

1.5229 mL

3.0458 mL

10 mM

0.1523 mL

0.7614 mL

1.5229 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (3.81 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.81 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[2]

Logarithmically growing Tca8113 cells are trypsinized and made into single cell suspension then plated in 96-well culture plate at a concentration of 5 × 10⁴ cells/well, eight columns for Teniposide and seven columns for CDDP in each plate, 3 wells in each column. After 24 hours of incubation, the medium of the 3 wells in each column are replaced with medium containing Teniposide of 0.15 mg/L, 0.5 mg/L, 1.5 mg/L, 5.0 mg/L, 15 mg/L and 45 mg/L or CDDP of 0.1 mg/L, 0.3 mg/L, 1.0 mg/L, 3.0 mg/L and 9.0 mg/L, respectively. Blank control wells are added medium without drugs. Cells are then cultured for another 24 hours, 48 hours, 72 hours, 96 hours and 120 hours. The supernatants are removed and 20 μL MTT solution is added in each well, followed with another 4 hours of culture. The supernatants are discarded carefully and 200 μL dimethyl sulphoxide (DMSO) is added and shaken vigorously to dissolve the purple precipitation formation. Optical density (OD) of each well is tested using Spectrophotometer with a wavelength of 450 nm. The experiment is repeated in triplicate^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Animals (mice) are treated with 0.5 mg/kg teniposide and bone marrow is sampled 24 h after treatment. Colchicine and mitomycin C are used as a positive control aneugen and clastogen, respectively, at the dose of 2 mg/kg each. Bone marrow smears are prepared and stained with May-Gruenwald/Giemsa solutions. At least four slides are made for each animal and allowed to dry overnight. One slide per animal is stained with May-Gruenwald/Giemsa solutions for conventional assessment of the micronuclei (MN) frequencies in polychromatic erythrocytes (PCEs) and normochromatic erythrocytes (NCEs). The remaining unstained slides are stored at −20°C for the distinction between the clastogenic and aneugenic effects by identifying the origin of MN with the mouse DNA probes. Per animal, 1000 PCE of coded slides are scored for the presence of MN. In addition, the number of PCEs among 1000 NCE per animal is recorded to evaluate bone marrow suppression and mitotic activity is calculated as %PCE = [PCE/(PCE + NCE)] × 100^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (290 KB)
SDS (418 KB)
- English - EN (418 KB)
- Français - FR (418 KB)
- Deutsch - DE (418 KB)
- Norwegian - NO (418 KB)
- Español - ES (418 KB)
- Swedish - SV (418 KB)
- Italian - IT (418 KB)
- Korean - KR (418 KB)
- Portuguese - PT (418 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Attia SM, et al. Molecular cytogenetic evaluation of the aneugenic effects of teniposide in somatic and germinal cells of male mice. Mutagenesis. 2012 Jan;27(1):31-9. [Content Brief]

[2]. Li J, et al. Topoisomerase II trapping agent teniposide induces apoptosis and G2/M or S phase arrest of oral squamous cell carcinoma. World J Surg Oncol. 2006 Jul 6;4:41. [Content Brief]

[3]. Sun YC, et al. MiR-181b sensitizes glioma cells to teniposide by targeting MDM2. BMC Cancer. 2014 Aug 25;14:611. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.5229 mL	7.6144 mL	15.2288 mL	38.0720 mL
	5 mM	0.3046 mL	1.5229 mL	3.0458 mL	7.6144 mL
	10 mM	0.1523 mL	0.7614 mL	1.5229 mL	3.8072 mL
	15 mM	0.1015 mL	0.5076 mL	1.0153 mL	2.5381 mL
	20 mM	0.0761 mL	0.3807 mL	0.7614 mL	1.9036 mL
	25 mM	0.0609 mL	0.3046 mL	0.6092 mL	1.5229 mL
	30 mM	0.0508 mL	0.2538 mL	0.5076 mL	1.2691 mL
	40 mM	0.0381 mL	0.1904 mL	0.3807 mL	0.9518 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Teniposide

Cell Cycle/DNA Damage Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Anti-Lung Cancer Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Blood Cancer Compound Library

Targeted Diversity Library

Tumorigenesis-Related Compound Library

Rare Diseases Drug Library

Chemotherapy Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

Biotoxin Library

Publications Citing Use of MedChemExpress (MCE) Teniposide

All Topoisomerase Isoforms

Biological Activity

Chemical Information

Publications (13)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Teniposide Related Classifications

HY-13761 Related Classifications